WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

WMT

89.87

+1.27%↑

COST

966.28

+1.27%↑

TGT

105.83

+1.54%↑

KR

67.29

-1.25%↓

GIS

59.21

-0.8%↓

Search

Hims & Hers Health Inc

Затворен

СекторДефанзивни потребителски стоки

31.15 0.48

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

28.94

Максимум

31.21

Ключови измерители

By Trading Economics

Приходи

-50M

26M

Продажби

80M

481M

P/E

Средно за сектора

54.722

44.466

EPS

0.227

Марж на печалбата

5.409

Служители

1,637

EBITDA

-8.2M

19M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+49.76% upside

Дивиденти

By Dow Jones

Следващи печалби

5.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-4.7B

6.5B

Предишно отваряне

30.67

Предишно затваряне

31.15

Настроения в новините

By Acuity

18%

82%

9 / 152 Класиране в Consumer defensive

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Hims & Hers Health Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.04.2025 г., 23:15 ч. UTC

Значими двигатели на пазара

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25.02.2025 г., 15:33 ч. UTC

Значими двигатели на пазара

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18.11.2024 г., 19:07 ч. UTC

Значими двигатели на пазара

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14.10.2024 г., 15:02 ч. UTC

Значими двигатели на пазара

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3.10.2024 г., 11:28 ч. UTC

Значими двигатели на пазара

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

2.04.2025 г., 16:53 ч. UTC

Топ новини

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19.03.2025 г., 15:54 ч. UTC

Топ новини

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21.02.2025 г., 23:20 ч. UTC

Печалби

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10.02.2025 г., 12:00 ч. UTC

Топ новини

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19.12.2024 г., 17:16 ч. UTC

Топ новини

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19.12.2024 г., 15:14 ч. UTC

Топ новини

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19.12.2024 г., 15:02 ч. UTC

Топ новини

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16.12.2024 г., 13:47 ч. UTC

Топ новини

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16.12.2024 г., 07:00 ч. UTC

Топ новини

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3.10.2024 г., 14:45 ч. UTC

Топ новини

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3.10.2024 г., 13:12 ч. UTC

Топ новини

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3.10.2024 г., 11:45 ч. UTC

Топ новини

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3.10.2024 г., 10:14 ч. UTC

Топ новини

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2.08.2024 г., 17:52 ч. UTC

Придобивния, сливания и поглъщания

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26.06.2024 г., 11:00 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24.05.2024 г., 20:37 ч. UTC

Печалби

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Hims & Hers Health Inc Прогноза

Ценова цел

By TipRanks

49.76% нагоре

12-месечна прогноза

Среден 46.5 USD  49.76%

Висок 85 USD

Нисък 21 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Hims & Hers Health Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

13 ratings

5

Купи

6

Задържане

2

Продай

Техническа оценка

By Trading Central

31.0237 / 31.88Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bullish Evidence

Настроение

By Acuity

9 / 152 Класиране в Дефанзивни потребителски стоки

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.